Development of a Dengue Vaccine

Period of Performance: 01/01/1988 - 12/31/1988

$553K

Phase 2 SBIR

Recipient Firm

Hawaii Biotech, Inc.
HONOLULU, HI 96817
Principal Investigator

Abstract

DENGUE VIRUS IS A POSITIVE SENSE, SINGLE STRANDED RNA VIRUS TRANSMITTED TO MAN BY MOSQUITOS. TOWARD DEVELOPING A VACCINE FOR DENGUE TYPE 2 VIRUS, A LIBRARY OF RANDOMLY PRIMED cDNA FRAGMENTS REPRESENTING THE DENGUE RNA GENOME HAS BEEN CLONED IN THE BACTERIOPHAGE EXPRESSION VECTOR LAMBDA/gtll. INSERT FRAGMENT SIZES AVERAGE ABOVE 100 BASE PAIRS, WHICH IS SUFFICIENT TO ENCODE 33 AMINO ACID RESIDUES AS A PEPTIDE FUSED TO BETAGALACTOSIDASE. WE PROPOSE TO SCREEN THE LIBRARY WITH HUMAN CONVALESCENT ANTISERA FOR RECOMBINANTS EXPRESSING DENGUE ANTIGENS. THE DNA SEQUENCE OF THE RECOMBINANTS WILL BE DETERMINED, AND THE CORRESPONDING FUSION PROTEINS AFTER PURIFICATION WILL BE USED TO ELICIT ANTISERA. THE ELICITED ANTIBODIES THEN WILL BE TESTED FOR HEMAGGLUTINE-TIONINHIBITING AND DENGUE VIRUS NEUTRALIZING ACTIVITY. IN THIS MANNER, WE WILL BE ABLE TO IDENTIFY AND CHARACTERIZE DENGUE PEPTIDES AND THEIR CORRESPONDING SEQUENCES THAT ARE CANDIDATES FOR VACCINES.